The Pulse
Evvy Raises $40 Million to Turn Vaginal Data Into AI Research
Evvy raises a $40 million Series B led by Catalio Capital Management to expand its vaginal microbiome platform and women’s-health research. The company plans to use its 100,000-patient dataset to study fertility, IVF outcomes, and new diagn
AI.info Team ·
Evvy’s 100,000-patient dataset becomes the company’s next business
Evvy has raised $40 million in Series B funding to turn a dataset built from more than 100,000 patients’ vaginal microbiomes into a research platform for women’s health. Catalio Capital Management led the round, which will fund new studies, expand Evvy’s data and artificial-intelligence capabilities, and broaden the company’s consumer testing business.
New York-based Evvy is best known for an at-home vaginal-health test that uses metagenomic sequencing to identify bacteria and fungi in a sample. The company pairs the test with clinical care for conditions including bacterial vaginosis and other recurring symptoms. Its longer-term plan is to use the biological data collected through that service to identify markers linked to disease, treatment response, and reproductive outcomes.
“There’s so much third-party research showing that the vaginal microbiome plays a role in so much of women’s health, and we finally have built the dataset to really answer those questions,” cofounder and CEO Priyanka Jain told Fortune.
Fertility is Evvy’s first research target
Evvy plans to begin the next phase of its work with fertility. One project collects samples from patients at IVF clinics to examine whether markers of infection and inflammation in the vaginal microbiome can help predict implantation success or failure.
The company says its fertility work is designed to add microbiome results to a broader clinical picture rather than treat the vaginal microbiome as a standalone explanation for an IVF outcome. That distinction matters because fertility involves multiple biological systems, and Evvy’s current studies are intended to test whether microbial signals add useful information to existing care.
Evvy has already published research on its test methodology and patient outcomes. The company’s science materials describe an ongoing prospective study examining potential microbial markers associated with IVF success, conducted with fertility physicians. The Series B will support validation of studies already in progress and additional research projects.
EvvyAI connects testing with biomarker discovery
The company describes EvvyAI as the machine-learning engine built on its vaginal microbiome dataset. Evvy uses the system to interpret test results, support personalized care pathways, and search for biological patterns that may become useful diagnostic markers. Its stated goal is to develop models that can connect microbial profiles with symptoms, recurrence patterns, and longer-term health outcomes.
Evvy’s existing work on bacterial vaginosis illustrates the approach. The company says its analysis found that patients who meet the same broad clinical criteria can have different microbial profiles and different recurrence patterns. In its research materials, Evvy reports identifying distinct bacterial vaginosis subtypes rather than treating the condition as a single biological state.
The company’s public science page says its platform has contributed to more than 15 peer-reviewed publications and abstracts. It also says the dataset includes more than 100,000 patient records and has supported the identification of previously uncatalogued vaginal microbiome genomes. Those claims come from Evvy; the funding announcement does not establish that every research finding has translated into a clinically validated diagnostic.
The consumer-versus-biotech question
Jain said Evvy faced pressure from investors to choose between being a consumer-health company and a biotechnology company. Consumer investors asked why the company was devoting resources to research instead of becoming a supplements business, she said, while biotech investors questioned why a company with a large dataset continued to invest in a consumer brand.
Evvy intends to keep both sides of the business. The new funding will expand its research capabilities while also placing greater emphasis on distribution through doctors’ offices. That model gives the company a way to collect additional clinical data while making its testing service part of routine care rather than relying only on direct-to-consumer sales.
“I felt almost like I was back in 2020,” Jain said, describing the education required when Evvy approached growth-stage investors. “We’re kind of in that early crop of companies that are graduating to that stage, and there was a lot of education to do.”
Priyanka Jain, cofounder and CEO, Evvy
What the $40 million has to prove
Evvy’s funding gives it the resources to move from an at-home testing company with a large proprietary dataset toward a research and clinical-development business. The immediate test is whether its microbiome measurements can produce markers that hold up in fertility studies and help physicians make better decisions for IVF patients.
The company also must show that its AI systems add value beyond sequencing and reporting. A larger dataset can reveal more patterns, but those patterns still need clinical validation before they can guide treatment or predict outcomes. Evvy’s next studies will determine whether its research engine can turn vaginal microbiome data into tools that clinicians can use.